Dermavant Announces Highly Favorable Results from Pediatric Maximal Usage Study of VTAMA® (tapinarof) cream, 1% in Atopic Dermatitis

LONG BEACH, Calif. & BASEL, Switzerland--(BUSINESS WIRE)--Dermavant Announces Highly Favorable Results from Pediatric Maximal Usage Study of VTAMA® (tapinarof) cream, 1% in Atopic Dermatitis

Click to view original post